Year: 2020

NoHo Partners PlcSTOCK EXCHANGE RELEASE 13 November 2020 at 14:15The Board of Directors of NoHo Partners Plc has on 9 November 2020 resolved on a directed share issue without payment to the key employees of the company in order to pay the reward for the first earning period of the long-term share-based incentive plan from 1 December 2018 to 31 December 2019. The stock exchange release concerning the directed share issue without payment was published on 9 November 2020.A total of 68 597 new shares of NoHo Partners Plc subscribed in the directed share issue without payment have been registered into the Trade Register on 13 November 2020 and admitted into the book-entry system of Euroclear Finland Oy. Following the registration of the new shares, the total number of shares in NoHo Partners Plc is 19 222 270. The new shares are intended to...

NoHo Partners OyjPÖRSSITIEDOTE 13.11.2020 klo 14.15NoHo Partners Oyj:n hallitus on 9.11.2020 päättänyt suunnatusta maksuttomasta osakeannista yhtiön avainhenkilöille osakepalkkiojärjestelmän ensimmäiseltä ansaintajaksolta 1.12.2018-31.12.2019 ansaitun palkkion maksamiseksi. Suunnatusta maksuttomasta osakeannista on tiedotettu 9.11.2020 julkaistulla pörssitiedotteella.NoHo Partners Oyj:n suunnatussa maksuttomassa osakeannissa 68 597 yhtiön uutta osaketta on rekisteröity 13.11.2020 kaupparekisteriin ja liitetty Euroclear Finland Oy:n ylläpitämään arvo-osuusjärjestelmään. Uusien osakkeiden rekisteröinnin myötä NoHo Partners Oyj:n osakkeiden kokonaismäärä on 19 222 270 osaketta. Uudet osakkeet on tarkoitus ottaa julkisen kaupankäynnin kohteeksi Nasdaq Helsinki Oy:n pörssilistalla arviolta 16.11.2020.Lisätietoja:Aku Vikström, toimitusjohtaja,...

TORONTO, Nov. 13, 2020 (GLOBE NEWSWIRE) — RioCan Real Estate Investment Trust (“RioCan”) (TSX: REI.UN) today announced a distribution of 12 cents per unit for the month of November. The distribution will be payable on December 7, 2020 to unitholders of record as at November 30, 2020.About RioCanRioCan is one of Canada’s largest real estate investment trusts. RioCan owns, manages and develops retail-focused, increasingly mixed-use properties located in prime, high-density transit-oriented areas where Canadians want to shop, live and work. As at September 30, 2020, our portfolio is comprised of 221 properties with an aggregate net leasable area of approximately 38.4 million square feet (at RioCan’s interest) including office, residential rental and 16 development properties.Information contact:Kim LeeVice President, Investor...

All amounts in U.S. dollars unless otherwise statedTORONTO, Nov. 13, 2020 (GLOBE NEWSWIRE) — Onex Corporation (TSX: ONEX) today announced its financial results for the third-quarter and nine-months ended September 30, 2020 and an update on matters following quarter end.“Building on our portfolio improvements last quarter, we continue to demonstrate increased momentum in our private equity and credit portfolios, resulting in a very good quarter for Onex,” said Gerry Schwartz, Chairman and Chief Executive Officer of Onex. “Earlier this quarter, I was delighted to announce Bobby Le Blanc as President of Onex, in recognition of his leadership ability and the positive role he continues to play in our success.”HighlightsOnex reported segment net earnings for the three months ended September 30, 2020 of $515 million ($5.39 per fully diluted...

HOUSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2020 and provided an update on recent corporate developments.“We made meaningful progress across our programs throughout the third quarter despite continued headwinds related to the COVID-19 pandemic. Importantly, enrollment continues in Stage 2 of our Phase 2 trial of prexigebersen (BP1001), a liposomal Grb2 antisense, as a combination treatment for patients suffering with acute myeloid leukemia (AML),” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. “We further strengthened...

Sensyne Health appoints President, North America, tolead US expansion      Oxford, U.K. 13 November 2020: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, announces that it has appointed Derek Baird to its senior management team as President, North America. Derek will join Sensyne on 01 December 2020 and will focus on driving the commercial development of the Company’s North American operations, building Sensyne’s presence in the US and recruiting a US-based team.Derek joins Sensyne from AVIA, a digital transformation partner for health systems and payers, where he served as Senior Vice President, Growth. Prior to joining AVIA Derek was a Senior Vice President at healthcare software company Health Language (acquired by Wolters Kluwer Health), and has held senior product and marketing...

CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced third quarter 2020 financial results and provided an update on recent progress.“We are enthusiastic as we advance CMP-001 toward registration in melanoma and expand toward potential proof of concept in additional indications,” said Barry Labinger, Chief Executive Officer. “We remain on track to initiate key new clinical trials by late 2020/early 2021 as planned.”Recent ProgressDuring SITC’s 35th Anniversary Annual Meeting, three new data presentations were given evaluating CMP-001, Checkmate’s advanced generation Toll-like receptor 9 (TLR9) agonist. These data...

– Seed Therapeutics to Use Proprietary “Molecular Glue” Protein Degradation Technology to Develop Potential New Medicines –NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) — Seed Therapeutics (“the Company”), a global research company and subsidiary of BeyondSpring focused on discovering and developing “molecular glues” to degrade disease-causing protein previously believed to be undruggable, announced today that it has entered into a research collaboration and license agreement with Eli Lilly and Company (“Lilly”) to discover and develop new chemical entities (NCEs) that could produce therapeutic benefit through targeted protein degradation (TPD).The TPD field allows for the targeting of hundreds of proteins that are known to be associated with human diseases but were previously thought to be undruggable. Seed Therapeutics has...